Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Weekly insulin 287 versus daily insulin glargine U100 in insulin-naive adults with type 2 diabetes mellitus
2018-003406-11Phase 2Completed
- Sponsor
- Novo Nordisk
- Start
- Jan 2019
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2 trial of insulin icodec and insulin glargine in type 2 diabetes mellitus (T2DM) (4 arms), sponsored by Novo Nordisk. Primary endpoint: Time in target range 3.9-10.0 mmol/L (70-180 mg/dL). Started Jan 2019; status: completed.
02
Drugs
insulin icodecinsulin glargine
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2018-003406-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003406-11.